Abstract
A mutation in codon 122 of the mouse p53 gene resulting in a T to L amino acid substitution (T122→L) is frequently associated with skin cancer in UV-irradiated mice that are both homozygous mutant for the nucleotide excision repair (NER) gene Xpc (Xpc−/−) and hemizygous mutant for the p53 gene. We investigated the functional consequences of the mouse T122→L mutation when expressed either in mammalian cells or in the yeast Saccharomyces cerevisiae. Similar to a non-functional allele, high expression of the T122→L allele in p53−/− mouse embryo fibroblasts and human Saos-2 cells failed to suppress growth. However, the T122→L mutant p53 showed wild-type transactivation levels with Bax and MDM2 promoters when expressed in either cell type and retained transactivation of the p21 and the c-Fos promoters in one cell line. Using a recently developed rheostatable p53 induction system in yeast we assessed the T122→L transactivation capacity at low levels of protein expression using 12 different p53 response elements (REs). Compared to wild-type p53 the T122→L protein manifested an unusual transactivation pattern comprising reduced and enhanced activity with specific REs. The high incidence of the T122→L mutant allele in the Xpc−/− background suggests that both genetic and epigenetic conditions may facilitate the emergence of particular functional p53 mutations. Furthermore, the approach that we have taken also provides for the dissection of functions that may be retained in many p53 tumor alleles.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ashcroft M, Vousden KH . 1999 Oncogene 18: 7637–7643
Aurelio ON, Kong XT, Gupta S, Stanbridge EJ . 2000 Mol. Cell. Biol. 20: 770–778
Blagosklonny MV, Giannakakou P, Romanova LY, Ryan KM, Vousden KH, Fojo T . 2001 Carcinogenesis 22: 861–867
Brachmann RK, Vidal M, Boeke JD . 1996 Proc. Natl. Acad. Sci. USA 93: 4091–4095
Brash DE, Ponten J . 1998 Cancer Surv. 32: 69–113
Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ . 1996 J. Investig. Dermatol. Symp. Proc. 1: 136–142
Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA, Iggo R, Fronza G . 2001 Oncogene 20: 3573–3579
Cheo DL, Meira LB, Burns DK, Reis AM, Issac T, Friedberg EC . 2000 Cancer Res. 60: 1580–1584
Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA . 1998 Oncogene 17: 1681–1689
el-Deiry WS . 1998 Semin. Cancer Biol. 8: 345–357
el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B . 1992 Nat. Genet. 1: 45–49
Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M . 1999 Mol. Cell. Biol. 19: 2594–2600
Espinosa JM, Emerson BM . 2001 Mol. Cell 8: 57–69
Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, Tada M, van Meir EG, Estreicher A, Iggo RD . 1995 Proc. Natl. Acad. Sci. USA 92: 3963–3967
Flaman JM, Robert V, Lenglet S, Moreau V, Iggo R, Frebourg T . 1998 Oncogene 16: 1369–1372
Frazier MW, He X, Wang J, Gu Z, Cleveland JL, Zambetti GP . 1998 Mol. Cell. Biol. 18: 3735–3743
Freeman J, Schmidt S, Scharer E, Iggo R . 1994 EMBO J. 13: 5393–5400
Ginsberg D, Mechta F, Yaniv M, Oren M . 1991 Proc. Natl. Acad. Sci. USA 88: 9979–9983
Gorospe M, Cirielli C, Wang X, Seth P, Capogrossi MC, Holbrook NJ . 1997 Oncogene 14: 929–935
Gottifredi V, Shieh S, Taya Y, Prives C . 2001 Proc. Natl. Acad. Sci. USA 98: 1036–1041
Hainaut P, Hollstein M . 2000 Adv. Cancer Res. 77: 81–137
Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P . 1999 Hum. Mutat. 14: 1–8
Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB . 1999 Science 285: 898–900
Holmquist GP, Gao S . 1997 Mutat. Res. 386: 69–101
Hussain SP, Harris CC . 1999 Mutat. Res. 428: 23–32
Inga A, Monti P, Fronza G, Darden T, Resnick MA . 2001 Oncogene 20: 501–513
Inga A, Resnick MA . 2001 Oncogene 20: 3409–3419
Kaeser MD, Iggo RD . 2002 Proc. Natl. Acad. Sci. USA 99: 95–100
Kieser A, Weich HA, Brandner G, Marme D, Kolch W . 1994 Oncogene 9: 963–969
Ko LJ, Prives C . 1996 Genes Dev. 10: 1054–1072
Lane D . 2001 Nature 414: 25–27
Lee YI, Lee S, Das GC, Park US, Park SM . 2000 Oncogene 19: 3717–3726
Lin J, Teresky AK, Levine AJ . 1995 Oncogene 10: 2387–2390
Ludwig RL, Bates S, Vousden KH . 1996 Mol. Cell. Biol. 16: 4952–4960
MacCallum DE, Hupp TR, Midgley CA, Stuart D, Campbell SJ, Harper A, Walsh FS, Wright EG, Balmain A, Lane DP, Hall PA . 1996 Oncogene 13: 2575–2587
McLure KG, Lee PW . 1998 EMBO J. 17: 3342–3350
Meek DW . 1999 Oncogene 18: 7666–7675
Munsch D, Watanabe-Fukunaga R, Bourdon JC, Nagata S, May E, Yonish-Rouach E, Reisdorf P . 2000 J. Biol. Chem. 275: 3867–3872
Murphy KL, Dennis AP, Rosen JM . 2000 FASEB J. 14: 2291–2302
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y . 2000 Cell 102: 849–862
Offer H, Milyavsky M, Erez N, Matas D, Zurer I, Harris CC, Rotter V . 2001 Oncogene 20: 581–589
Pantoja C, Serrano M . 1999 Oncogene 18: 4974–4982
Prives C, Hall PA . 1999 J. Pathol. 187: 112–126
Reis AM, Cheo DL, Meira LB, Greenblatt MS, Bond JP, Nahari D, Friedberg EC . 2000 Cancer Res. 60: 1571–1579
Rodin SN, Holmquist GP, Rodin AS . 1998 Int. J. Mol. Med. 1: 191–199
Sage E, Lamolet B, Brulay E, Moustacchi E, Chateauneuf A, Drobetsky EA . 1996 Proc. Natl. Acad. Sci. USA 93: 176–180
Saller E, Tom E, Brunori M, Otter M, Estreicher A, Mack DH, Iggo R . 1999 EMBO J. 18: 4424–4437
Scharer E, Iggo R . 1992 Nucleic Acids Res. 20: 1539–1545
Smith ML, Ford JM, Hollander MC, Bortnick RA, Amundson SA, Seo YR, Deng CX, Hanawalt PC, Fornace Jr AJ . 2000 Mol. Cell. Biol. 20: 3705–3714
Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Gusterson BA, Allday MJ, Crook T . 1999 Oncogene 18: 2451–2459
Storici F, Lewis LK, Resnick MA . 2001 Nat. Biotechnol. 19: 773–776
Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K . 2000 Cell Death Differ. 7: 721–728
Szak ST, Mays D, Pietenpol JA . 2001 Mol. Cell. Biol. 21: 3375–3386
Takeuchi S, Nakatsu Y, Nakane H, Murai H, Hirota S, Kitamura Y, Okuyama A, Tanaka K . 1998 Cancer Res. 58: 641–646
Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y . 2000 Nature 404: 42–49
Thornborrow EC, Manfredi JJ . 1999 J. Biol. Chem. 274: 33747–33756
Thornborrow EC, Manfredi JJ . 2001 J. Biol. Chem. 276: 15598–15608
van Oosten M, Rebel H, Friedberg EC, van Steeg H, van der Horst GT, van Kranen HJ, Westerman A, van Zeeland AA, Mullenders LH, de Gruijl FR . 2000 Proc. Natl. Acad. Sci. USA 97: 11268–11273
Vogelstein B, Lane D, Levine AJ . 2000 Nature 408: 307–310
Volker M, Mone MJ, Karmakar P, van Hoffen A, Schul W, Vermeulen W, Hoeijmakers JH, van Driel R, van Zeeland AA, Mullenders LH . 2001 Mol. Cell 8: 213–224
Wang YA, Elson A, Leder P . 1997 Proc. Natl. Acad. Sci. USA 94: 14590–14595
Wieczorek AM, Waterman JL, Waterman MJ, Halazonetis TD . 1996 Nat. Med. 2: 1143–1146
Wijnhoven SW, Kool HJ, Mullenders LH, van Zeeland AA, Friedberg EC, van der Horst GT, van Steeg H, Vrieling H . 2000 Oncogene 19: 5034–5047
Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B . 1999 Proc. Natl. Acad. Sci. USA 96: 14517–14522
Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M . 1995 Nucleic Acids Res. 23: 2584–2592
Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ . 2000 Genes Dev. 14: 981–993
Acknowledgements
Our thanks to Dr Antonio Reis for the gift of the tumor RNA samples, to Drs Richard Iggo, Thierry Frebourg, Bert Vogelstein and Moshe Oren for the generous gifts of expression vectors and yeast strains, and to Drs Robbert Slebos, Dmitry Gordenin, Francesca Storici, Gilberto Fronza for advice, helpful discussions and comments on the manuscript. We also thank Russell Daniel and Bonnie Ferguson Darnell for valuable technical support. Alberto Inga was supported by an NIH Courtesy Contract.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Inga, A., Nahari, D., Velasco-Miguel, S. et al. A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions. Oncogene 21, 5704–5715 (2002). https://doi.org/10.1038/sj.onc.1205779
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205779
Keywords
This article is cited by
-
Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson
Oncogene (2007)
-
Xeroderma pigmentosum group C gene expression is predominantly regulated by promoter hypermethylation and contributes to p53 mutation in lung cancers
Oncogene (2007)
-
The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response
Cell Research (2004)